A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs

NCT06423170 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Unresectable Gallbladder Cancer

Interventions

DRUG: Camrelizumab plus GEMOX

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University